Half-Yearly Report on Genkyotex’s Liquidity Contract With Kepler Cheuvreux
12 Gennaio 2021 - 8:07PM
Business Wire
Regulatory News:
Pursuant to the liquidity contract granted by Genkyotex
(Paris:GKTX) (Brussels:GKTX) to Kepler Cheuvreux, effective May 7,
2018, the following assets appeared on the liquidity account as of
December 31, 2020:
- 9,243 Genkyotex shares,
- 13,467.52 € in cash.
During the period of 01/07/2020 to 31/12/2020, the following has
been executed: - 147 executions on buy side - 127 executions on
sell side
During the same period, the volume traded was as follows: -
18,814 shares for 47,956.14 euros on buy side - 21,036 shares for
54,129.05 euros on sell side
As a reminder, under the liquidity contract the following assets
appeared on the liquidity account at June 30, 2020:
- 11,465 Genkyotex shares,
- 7,330.03 € in cash.
During the period of 01/01/2020 to 30/06/2020, the following has
been executed: - 262 executions on buy side - 185 executions on
sell side
During the same period, the volume traded was as follows: -
71,504 shares for 154,179.10 euros on buy side - 67,828 shares for
147,094.25 euros on sell side
About Genkyotex
Genkyotex is the leading biopharmaceutical company in NOX
therapies, listed on the Euronext Paris and Euronext Brussels
markets. Its unique platform enables the identification of orally
available small-molecules which selectively inhibit specific NOX
enzymes that amplify multiple disease processes such as fibrosis,
inflammation, pain processing, cancer development, and
neurodegeneration. Genkyotex is developing a pipeline of
first-in-class product candidates targeting one or multiple NOX
enzymes. The lead product candidate, setanaxib (GKT831), a NOX1 and
NOX4 inhibitor has shown evidence of anti-fibrotic activity in a
Phase II clinical trial in primary biliary cholangitis (PBC, a
fibrotic orphan disease). Based on its positive Phase II results, a
phase 3 trial with setanaxib in PBC is being planned. Setanaxib is
also being evaluated in an investigator-initiated Phase II clinical
trial in Type 1 Diabetes and Kidney Disease (DKD). A grant from the
United States National Institutes of Health (NIH) of $8.9 million
was awarded to Professor Victor Thannickal at the University of
Alabama at Birmingham (UAB) to fund a multi-year research program
evaluating the role of NOX enzymes in idiopathic pulmonary fibrosis
(IPF), a chronic lung disease that results in fibrosis of the
lungs. The core component of this program is a Phase 2 trial with
setanaxib in patients suffering from IPF for which the first
patient has been enrolled in September 2020. This product candidate
may also be active in other fibrotic indications.
Genkyotex also has a versatile platform well-suited to the
development of various immunotherapies (Vaxiclase). A partnership
covering the use of Vaxiclase as an antigen per se (GTL003) has
been established with Serum Institute of India Private Ltd (Serum
Institute), the world’s largest producer of vaccine doses, for the
development by Serum Institute of cellular multivalent combination
vaccines against a variety of infectious diseases.
For further information, please go to
www.genkyotex.com
Disclaimer
This announcement does not constitute an invitation to
participate in the on-going tender offer on Genkyotex shares or to
tender Genkyotex’ shares in or from any jurisdiction in or from
which, or to or from any person to or from whom, it is unlawful to
make such invitation under applicable securities laws. The
distribution of this announcement in certain jurisdictions may be
restricted by law. Persons into whose possession this announcement
comes are required to inform themselves about, and to observe, any
such restrictions.
This press release may contain forward-looking statements by the
company with respect to its objectives. Such statements are based
upon the current beliefs, estimates and expectations of Genkyotex’s
management and are subject to risks and uncertainties such as the
company's ability to implement its chosen strategy, customer market
trends, changes in technologies and in the company's competitive
environment, changes in regulations, clinical or industrial risks
and all risks linked to the company's growth. These factors as well
as other risks and uncertainties may prevent the company from
achieving the objectives outlined in the press release and actual
results may differ from those set forth in the forward-looking
statements, due to various factors. Without being exhaustive, such
factors include uncertainties involved in the development of
Genkyotex’s products, which may not succeed, or in the delivery of
Genkyotex’s products marketing authorizations by the relevant
regulatory authorities and, in general, any factor that could
affects Genkyotex’s capacity to commercialize the products it
develops. No guarantee is given on forward-looking statements which
are subject to a number of risks, notably those described in the
universal registration document filed with the AMF on April 30,
2020 under number D.20-0434, and those linked to changes in
economic conditions, the financial markets, or the markets on which
Genkyotex is present. Genkyotex products are currently used for
clinical trials only and are not otherwise available for
distribution or sale.
Buy Side
Sell Side
Number of executions
Number of shares
Traded volume in EUR
Number of executions
Number of shares
Traded volume in EUR
Total
147
18,814
47,956.14
127
21,036
54,129.05
01/07/2020
6
501
1,102.20
1
1
2.26
02/07/2020
-
-
-
3
500
1,100.00
03/07/2020
3
115
253.00
5
501
1,122.24
06/07/2020
3
186
409.20
-
-
-
07/07/2020
1
1
2.20
5
2,108
4,785.16
09/07/2020
2
301
668.22
6
1,001
2,252.25
10/07/2020
1
1
2.27
1
1
2.27
13/07/2020
3
601
1,346.24
1
1
2.25
14/07/2020
4
301
668.22
1
1
2.23
15/07/2020
1
300
660.00
2
700
1,589.00
16/07/2020
1
1
2.21
1
1
2.21
17/07/2020
1
1
2.24
6
501
1,132.26
20/07/2020
6
1,266
2,949.78
12
3,092
7,358.96
21/07/2020
18
1,934
4,390.18
10
1,400
3,248.00
22/07/2020
6
601
1,358.26
2
2
4.72
23/07/2020
1
200
452.00
4
400
916.00
24/07/2020
3
405
903.15
1
200
452.00
27/07/2020
6
1,095
2,419.95
5
600
1,344.00
28/07/2020
3
401
882.20
4
401
894.23
29/07/2020
7
901
1,946.16
5
376
823.44
30/07/2020
3
501
1,052.10
1
1
2.15
31/07/2020
-
-
-
1
1
2.14
04/08/2020
1
91
189.28
4
724
1,563.84
05/08/2020
3
22
47.08
2
201
442.20
06/08/2020
2
21
44.94
4
401
886.21
07/08/2020
3
392
834.96
1
1
2.20
10/08/2020
4
756
1,632.96
-
-
-
12/08/2020
1
1
2.20
2
2
4.40
14/08/2020
2
500
1,440.00
-
-
-
20/08/2020
1
1
2.93
1
1
2.93
21/08/2020
2
501
1,452.90
1
1
2.91
25/08/2020
1
1
2.94
1
1
2.94
26/08/2020
1
1
2.91
1
1
2.91
28/08/2020
-
-
-
1
21
62.16
01/09/2020
-
-
-
1
479
1,417.84
03/09/2020
1
1
2.96
1
1
2.96
08/09/2020
-
-
-
1
500
1,500.00
09/09/2020
-
-
-
1
1,000
3,100.00
10/09/2020
2
1,000
3,040.00
-
-
-
11/09/2020
3
161
492.66
1
1
3.08
14/09/2020
2
341
1,043.46
1
1
3.07
15/09/2020
-
-
-
1
1,000
3,100.00
17/09/2020
1
300
906.00
-
-
-
18/09/2020
2
117
352.17
4
1,000
3,060.00
21/09/2020
-
-
-
1
1,000
3,100.00
23/09/2020
1
1
3.05
5
1,001
3,083.08
25/09/2020
3
501
1,523.04
3
412
1,268.96
28/09/2020
2
384
1,155.84
1
1
3.05
29/09/2020
1
1
3.07
1
1
3.07
30/09/2020
1
1
3.05
1
1
3.05
01/10/2020
1
500
1,500.00
-
-
-
02/10/2020
1
1
3.03
1
1
3.03
05/10/2020
1
1
3.02
1
1
3.02
06/10/2020
7
501
1,523.04
1
1
3.05
08/10/2020
7
1,000
3,010.00
-
-
-
09/10/2020
3
500
1,500.00
-
-
-
12/10/2020
3
1,001
2,982.98
1
1
3.05
13/10/2020
2
200
600.00
-
-
-
15/10/2020
2
401
1,182.95
1
1
2.97
19/10/2020
-
-
-
3
1,000
3,000.00
22/10/2020
1
1
2.94
-
-
-
26/10/2020
-
-
-
1
490
1,455.30
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210112005994/en/
GENKYOTEX Alexandre Grassin CFO Tel.: +33 (0)5 61 28 70
60 investors@genkyotex.com NewCap Dušan Orešanský Tel.: +33
1 44 71 94 92 genkyotex@newcap.eu